2023 World Conference on Lung Cancer (Posters)-P2.06. Association of Clinical Response and HRQoL with Long-Term Survival with 1L Nivolumab + Ipilimumab in mNSCLC in CheckMate 227

P2.06. Association of Clinical Response and HRQoL with Long-Term Survival with 1L Nivolumab + Ipilimumab in mNSCLC in CheckMate 227 - PDF(Slides)

Back to course

Pdf Summary

CheckMate 227 Part 1 is a study that investigated the long-term survival benefits of nivolumab (NIVO) plus ipilimumab (IPI) compared to chemotherapy (chemo) in patients with metastatic non-small cell lung cancer (NSCLC). The study found that patients who had a clinical response at 6 months had better long-term overall survival (OS) with NIVO plus IPI compared to chemo. Specifically, 47% of responders in the NIVO plus IPI arm were alive 6 years later, compared to 22% in the chemo arm.<br /><br />Improved health-related quality of life (HRQoL) by 6 months was associated with improved long-term OS in patients receiving NIVO plus IPI, but not in those receiving chemo. The HR (95% CI) for improvement in HRQoL using the EQ-5D-3L visual analog scale (VAS) was 0.76 (0.59-0.99) for NIVO plus IPI, and 1.10 (0.86-1.40) for chemo. Similarly, for the EQ-5D-3L utility index (UI), the HR (95% CI) for improvement was 0.69 (0.53-0.89) for NIVO plus IPI and 1.09 (0.85-1.40) for chemo.<br /><br />The study also found that HRQoL improvement over time was associated with long-term OS benefit, regardless of treatment assignment. These results indicate the potential predictive value of tumor response and HRQoL improvement for the long-term efficacy benefit of first-line NIVO plus IPI in patients with metastatic NSCLC.<br /><br />In conclusion, the study highlights that patients who have a clinical response and improved HRQoL at 6 months have better long-term survival outcomes with NIVO plus IPI compared to chemotherapy. These findings suggest that early measurement of tumor response and HRQoL may be useful in predicting the effectiveness of NIVO plus IPI in treating metastatic NSCLC.

Asset Subtitle

Julie Brahmer

Meta Tag

Speaker Julie Brahmer

Topic Metastatic NSCLC: Immunotherapy - Prospective

Keywords

CheckMate 227 Part 1

nivolumab

ipilimumab

chemotherapy

metastatic non-small cell lung cancer

overall survival

health-related quality of life

EQ-5D-3L

tumor response

efficacy benefit